Opinion

Video

Emerging Data of Additional SERDs in Metastatic Breast Cancer

Panelists discuss recent data on other selective estrogen receptor degraders (SERDs) and their implications in the treatment of HR+/HER2– breast cancer.

Video content above is prompted by the following:

Dr. Bardia to Dr. Teplinsky: Please briefly mention recent data on other SERDs:

Related Videos
5 experts are featured in this series
5 experts are featured in this series
Eric Winer, MD
2 expert is featured in this series.
Related Content
Manish R. Patel, MD, of Florida Cancer Specialists
February 5th 2025

CLDN6-Directed Agents Generate Encouraging Early Activity in Solid Tumors

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Breast cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.co
February 3rd 2025

FDA Approves Companion Diagnostic for T-DXd in HER2-Ultralow Metastatic Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.
February 1st 2025

The OncFive: Top Oncology Articles for the Week of 1/26

Breast Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
January 31st 2025

Datopotamab Deruxtecan Wins CHMP Positive Opinion for Previously Treated HR+ Breast Cancer